Merck
CN

Role of SN1 lipases on plasma lipids in metabolic syndrome and obesity.

Arteriosclerosis, thrombosis, and vascular biology (2014-01-25)
Verónica Miksztowicz, Laura Schreier, Mary McCoy, Diego Lucero, Eduardo Fassio, Jeffrey Billheimer, Daniel J Rader, Gabriela Berg
摘要

To assess the phospholipase activity of endothelial (EL) and hepatic lipase (HL) in postheparin plasma of subjects with metabolic syndrome (MS)/obesity and their relationship with atherogenic and antiatherogenic lipoproteins. Additionally, to evaluate lipoprotein lipase (LPL) and HL activity as triglyceride (TG)-hydrolyses to complete the analyses of SN1 lipolytic enzymes in the same patient. Plasma EL, HL, and LPL activities were evaluated in 59 patients with MS and 36 controls. A trend toward higher EL activity was observed in MS. EL activity was increased in obese compared with normal weight group (P=0.009) and was negatively associated with high-density lipoprotein-cholesterol (P=0.014 and P=0.005) and apolipoprotein A-I (P=0.045 and P=0.001) in control and MS group, respectively. HL activity, as TG-hydrolase, was increased in MS (P=0.025) as well as in obese group (P=0.017); directly correlated with low-density lipoprotein-cholesterol (P=0.005) and apolipoprotein B (P=0.003) and negatively with high-density lipoprotein-cholesterol (P=0.021) in control group. LPL was decreased in MS (P<0.001) as well as in overweight and obese compared with normal weight group (P=0.015 and P=0.004, respectively); inversely correlated %TG-very low-density lipoproteins (P=0.04) and TG/apolipoprotein B index (P=0.013) in control group. These associations were not found in MS. We describe for the first time EL and HL activity as phospholipases in MS/obesity, being both responsible for high-density lipoprotein catabolism. Our results elucidate part of the remaining controversies about SN1 lipases activity in MS and different grades of obesity. The impact of insulin resistance on the activity of the 3 enzymes determines the lipoprotein alterations observed in these states.

材料
货号
品牌
产品描述

Sigma-Aldrich
脂肪酶 来源于皱褶假丝酵母, Type VII, ≥700 unit/mg solid
Sigma-Aldrich
脂肪酶 来源于猪胰腺, Type II, ≥125 units/mg protein (using olive oil (30 min incubation)), 30-90 units/mg protein (using triacetin)
Sigma-Aldrich
脂肪酶丙烯酸树脂, ≥5,000 U/g, recombinant, expressed in Aspergillus niger
Sigma-Aldrich
重组脂肪酶 B 南极假丝酵母 来源于米曲霉, powder, beige, ~9 U/mg
Sigma-Aldrich
脂肪酶 来源于猪胰腺, Type VI-S, ≥20,000 units/mg protein, lyophilized powder
Sigma-Aldrich
脂肪酶 来源于米曲霉, solution, ≥100,000 U/g, white, beige
Sigma-Aldrich
脂肪酶 来源于洋葱假单胞菌, powder, light beige, ≥30 U/mg
Sigma-Aldrich
脂蛋白脂肪酶 来源于假单胞菌 属, lyophilized, powder, ≥1200 U/mg
Sigma-Aldrich
脂肪酶 来源于黑曲霉, powder (fine), ~200 U/g
Sigma-Aldrich
脂肪酶 来源于皱褶假丝酵母, lyophilized powder, ≥40,000 units/mg protein
Sigma-Aldrich
脂肪酶 来源于念珠菌 属, recombinant, expressed in Aspergillus niger
Sigma-Aldrich
脂蛋白脂酶 来源于伯克霍尔德氏菌 属, lyophilized powder, ≥50,000 units/mg solid
Sigma-Aldrich
脂肪酶 来源于小麦胚芽, Type I, lyophilized powder, 5-15 units/mg solid
Sigma-Aldrich
固定化脂肪酶 来源于南极假丝酵母, beads, slightly brown, >2 U/mg
Sigma-Aldrich
脂肪酶 来源于米赫根毛霉, ≥20,000 U/g
Sigma-Aldrich
脂肪酶 来源于米根霉, powder (fine), ~10 U/mg
Sigma-Aldrich
脂肪酶 来源于假单胞菌 属, Type XIII, lyophilized powder, ≥15 units/mg solid
Sigma-Aldrich
脂蛋白脂酶 来源于牛奶, ammonium sulfate suspension, ≥2,000 units/mg protein (BCA)
Sigma-Aldrich
脂肪酶 来源于米曲霉, lyophilized, powder, white, ~50 U/mg
Sigma-Aldrich
脂肪酶 来源于米黑毛霉菌, powder, slightly brown, ~1 U/mg
Sigma-Aldrich
南极假丝酵母脂肪酶A,重组 来源于米曲霉, powder, beige, ~2 U/mg
Sigma-Aldrich
脂肪酶 来源于皱褶假丝酵母, powder, yellow-brown, ≥2 U/mg
Sigma-Aldrich
脂肪酶 来源于皱褶假丝酵母, lyophilized, powder (fine), 15-25 U/mg
Sigma-Aldrich
脂肪酶 来源于猪胰腺 来源于雪白根霉菌, powder (fine), ≥1.5 U/mg
Sigma-Aldrich
脂肪酶 来源于米黑毛霉菌, lyophilized powder, ≥4,000 units/mg solid (using olive oil)
Sigma-Aldrich
脂肪酶 来源于爪哇毛霉菌, lyophilized powder, ≥300 units/mg solid (using olive oil)
Sigma-Aldrich
脂蛋白脂肪酶 来源于假单胞菌 属, lyophilized, powder, yellow-brown, ≥160 U/mg